BridgeBio Pharma, Inc.

It out-grows 95% of companies worldwide.

Revenue grew 86%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 71%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 54%/yr over five years.10/10

Revenue grew 86%/yr over the last 3 years; forecasts see it cooling to 71%/yr.

The company is loss-making, so its revenue growth is not backed by profit yet.

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

Strong long-term results. Long-term holders have seen +165% over three years and +50% over five, ahead of 70% of the market.

It's up 23% over the past year, but 28% below its 52-week high. That is a touch ahead of the market.

The stock is underperforming over the past month (-11%), over three months (-14%) and so far this year (-12%).

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over the past month, over three months and so far this year.